Moody Lynn & Lieberson’s Neurocrine Biosciences NBIX Stock Holding History

Moody Lynn & Lieberson’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12M	Buy	+12,591	New	+$1.87M	0.11%	80
2024 Q2	–	Sell	-22,428	Closed	-$3.09M	–	244
2024 Q1	$3.09M	Buy	+22,428	New	+$3.06M	0.21%	77
2023 Q1	–	Sell	-34,645	Closed	-$4.14M	–	228
2022 Q4	$4.14M	Sell	34,645 -35	-0.1%	-$4.1K	0.38%	60
2022 Q3	$3.68M	Sell	34,680 -5	-0%	-$507	0.36%	61
2022 Q2	$3.38M	Buy	+34,685	New	+$3.2M	0.3%	66
2020 Q4	–	Sell	-10,351	Closed	-$995K	–	214
2020 Q3	$995K	Buy	+10,351	New	+$1.2M	0.1%	101
2018 Q4	–	Sell	-4,243	Closed	-$522K	–	204
2018 Q3	$522K	Buy	+4,243	New	+$481K	0.06%	151

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Moody Lynn & Lieberson's NBIX Position: Q2 2026 in Review

Moody Lynn & Lieberson opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 12,591 shares worth $2.12M. The stake represents 0.11% of the portfolio and ranks #80 among its holdings. This is a return to the name: Moody Lynn & Lieberson previously reported a position in NBIX as recently as Q1 2024.

Moody Lynn & Lieberson first reported a position in NBIX in Q3 2018 and has held it in 7 quarters since. The position peaked at $4.14M in Q4 2022. 108 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Moody Lynn & Lieberson held 12,591 shares of Neurocrine Biosciences worth $2.12M as of Q2 2026.
Neurocrine Biosciences was a new Moody Lynn & Lieberson position in Q2 2026.
Neurocrine Biosciences made up 0.11% of Moody Lynn & Lieberson's portfolio in Q2 2026, its #80 holding.
Moody Lynn & Lieberson first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 7 quarters since.
Moody Lynn & Lieberson's Neurocrine Biosciences position peaked at $4.14M in Q4 2022.
108 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Moody Lynn & Lieberson's 13F filing for Q2 2026, filed 20 Jul 2026.